Dublin, April 02, 2024 (GLOBE NEWSWIRE) -- The "ZONTIVITY Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering. The report provides ...

On May 8, 2017, Aralez Pharmaceuticals Inc. (ARLZ) announced financial results for the first quarter of 2017 and provided a business update. Total revenues for the first quarter of 2017 were $26.0 ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved vorapaxar to reduce the risk for MI, stroke, CV-related death and coronary ...

Merck & Co. ($MRK) has come to the end of the line with Zontivity, a clot-busting med once tagged with $5 billion sales estimates. The drugmaker won't promote the ...

The prescribing information for ZONTIVITY includes a boxed warning regarding bleeding risk. ZONTIVITY is not for use in patients with a history of stroke, TIA or intracranial hemorrhage (ICH), or ...

HealthEdge Investment Partners-backed Legacy-Xspire Holdings completed the acquisition of US and Canadian distribution rights for Zontivity from New American Therapeutics. The product will be marketed ...

Merck’s new cardiovascular treatment Zontivity (vorapaxar) has been approved by the FDA to reduce the risk of heart attack, stroke and death in high risk patients. Zontivity is the first in a new ...

The "ZONTIVITY Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering. ZONTIVITY, known for its efficacy in reducing thrombotic cardiovascular ...

SummaryGlobalData has released its new PharmaPoint Drug Evaluation report, "Zontivity (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023". The current ACS market - primarily comprised of ...

The U.S. Food and Drug Administration today approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore the blood flow ...